Key Takeaways
- • Cinven has agreed to acquire women's health pharmaceutical business Theramex from Carlyle and PAI Partners in a transaction valuing the company at approximately €2.6bn, according to the Financial Times.
- • The deal is a secondary buyout, with Theramex changing hands from Carlyle and PAI Partners to Cinven.
- • Brookfield is targeting a £20bn UK data-centre development, the second headline item in this deal roundup.
- • The primary source is a paywalled excerpt, so further deal terms, closing timelines, and financing details are not available from this source.
Summary
Cinven has agreed to acquire Theramex, a women's health pharmaceutical business, from its current owners Carlyle and PAI Partners. According to the Financial Times, the transaction values the company at approximately €2.6bn. The deal represents a secondary buyout, transferring ownership of the specialty pharma platform from one private equity sponsor group to another.
The same AltAssets Private Equity News roundup also reports that Brookfield is targeting a £20bn UK data-centre development. The available source text does not provide further detail on the project's scope, location, phasing, or financing structure.
Full details of both stories are restricted behind a premium subscription wall in the primary source, so the figures above reflect the publicly available excerpt and the attribution to the Financial Times.
The same AltAssets Private Equity News roundup also reports that Brookfield is targeting a £20bn UK data-centre development. The available source text does not provide further detail on the project's scope, location, phasing, or financing structure.
Full details of both stories are restricted behind a premium subscription wall in the primary source, so the figures above reflect the publicly available excerpt and the attribution to the Financial Times.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.